Distribution of treatment courses by antibiotic and number of courses with serum concentration at steady state (Css) above the established target for each group. A: dose reduction not required and no continuous renal replacement therapy (CRRT). B: dose reduction required and no CCRT. C: CRRT at any time during the observation period
| Antibiotic | Treatment courses n (% of drug cases) | Courses with all Css above target during 96 hours n (% of group) |
| Piperacillin-tazobactam (PTZ) | Global 70 (75.0) | 41 (58.6) |
| Group A, n (% PTZ) 29 (40.0) | 9 (31.0) | |
| Groups B and C, n (% PTZ) 41 (63.6) | 32 (78.0) | |
|
Specific therapy n (% PTZ) E . c oli 13 P. a eruginosa 7 Other 5 All 25 (37.9) | 15 (60.0) | |
| Empirical therapy n (% PTZ) 45 (64.3) | 26 (57.8) | |
| Meropenem (MEM) | Global 2325 | 16 (69.6) |
| Group A, n (% MEM) 14 (60.9) | 7 (50.0) | |
| Group B and C, n (% MEM) 9 (39.1) | 9 (100) | |
|
Specific therapy, n (% MEM)
E. c oli 12 P. a e r u ginosa 1 Other 1 All 14 (60.9) | 13 (92.8) | |
| Empirical therapy, n (% MEM) 9 (39.1) | 3 (33.3) | |
| Total | 93 (100) | 57 (61.3) |